A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome-Reference-Cited by-同舟云学术

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome

Published:2015-09-14 Issue:2 Volume:30 Page:268-273
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Daver N,Kantarjian H,Ravandi F,Estey E,Wang X,Garcia-Manero G,Jabbour E,Konopleva M,O'Brien S,Verstovsek S,Kadia T,Dinardo C,Pierce S,Huang X,Pemmaraju N,Diaz-Pines-Mateo M,Cortes J,Borthakur G

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2015244.pdf

Reference44 articles.

1. Kantarjian HM . Therapy for elderly patients with acute myeloid leukemia: a problem in search of solutions. Cancer 2007; 109: 1007–1010.

2. Kantarjian H, O’Brien S, Cortes J, Giles F, Faderl S, Jabbour E et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006; 106: 1090–1098.

3. Nazha A, Ravandi F . Acute myeloid leukemia in the elderly: do we know who should be treated and how? Leuk Lymphoma 2014; 55: 979–987.

4. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481–3485.

5. Tallman MS, Gilliland DG, Rowe JM . Drug therapy for acute myeloid leukemia. Blood 2005; 106: 1154–1163.

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma;Cell Reports Medicine;2024-04

2. Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window;Molecular Cancer Therapeutics;2024-04-01

3. Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes;Cancer Treatment Reviews;2024-02

4. Vaccines: a promising therapy for myelodysplastic syndrome;Journal of Hematology & Oncology;2024-01-08

5. The Use of Gemtuzumab Ozogamicin as Salvage Therapy in Patients with Acute Myeloid Leukemia: A Monocentric Real-World Experience;Medicina;2023-03-02